Free Submission Public Relations & NewsPR-inside.com
 
DeutschEnglish

Get the latest news
with our RSS feed
rss feed
Add to My Yahoo!
More information
Business

Optimer Pharmaceuticals to Present at BioCentury NewsMakers Conference


Print article Print article
Refer this article Refer to a friend
© Business Wire 2008
2008-08-28 14:06:06 -

www.optimerpharma.com - Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced today that the Company is scheduled to present on Thursday, September 4, 2008, at 1:30 p.m. ET at the NewsMakers in the Biotech Industry Conference at the Millennium Broadway Hotel in New York, NY.

A live audio webcast of this presentation will be available on the Company's

website at www.optimerpharma.com, on the investors page. Replays of this presentation will be available for thirty days after the meeting.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products for the treatment of serious infections. Optimer has two late-stage anti-infective product candidates. OPT-80 is being developed for the treatment of Clostridium difficile infection, the most common hospital-acquired diarrhea. Prulifloxacin is an antibiotic being developed for the treatment of travelers' diarrhea, a form of infectious diarrhea. Additional information can be found at www.optimerpharma.com.

Optimer Pharmaceuticals, Inc.
Christina Donaghy, Corporate Communications Manager
John D. Prunty, Chief Financial Officer & VP Finance
858-909-0736
or
Porter Novelli Life Sciences
Jason I. Spark, Vice President
619-849-6005


Disclaimer: (c) 2007 Business Wire. All of the news releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.


Terms & Conditions | About us | Contact PR-inside.com